{
  "id": 20740598,
  "title": "Health Ministry proposes to include antimicrobials in ‘New Drug’ definition, separate licence for bulk drug wholesale",
  "url": "https://urgent.news/2026/11/19/health-ministry-proposes-to-include-antimicrobials-in-new-drug",
  "topic": "world",
  "section": "World",
  "published": "2026-11-19T11:26:13.000Z",
  "source": {
    "name": "The Hindu",
    "slug": "the-hindu",
    "url": "https://www.thehindu.com/news/national/health-ministry-proposes-to-include-antimicrobials-in-new-drug-definition-separate-licence-for-bulk-drug-wholesale/article71719726.ece"
  },
  "original_language": "en",
  "account": "The Union Health Ministry has proposed an amendment to the New Drugs and Clinical Trials Rules, 2019, to categorize 'antimicrobials' as 'New Drugs' under Rule 2(1)(w)(v). This move comes in response to growing concerns about antimicrobial resistance (AMR) and the potential for granting manufacturing licences for antimicrobial products without sufficient regulatory oversight. The proposed amendment seeks to ensure that antimicrobials fall under the regulatory framework applicable to new drugs, subjecting them to stringent requirements such as bioavailability, bioequivalence, and stability studies.\n\nTo implement this change, manufacturers would be required to seek permission from the Central Licensing Authority before applying for a manufacturing licence from the relevant State Licensing Authority. This proposed regulation aims to bolster central regulatory oversight and maintain the quality, safety, and efficacy of antimicrobial products.\n\nAdditionally, the Ministry has suggested amendments to the Drugs Rules, 1945, to introduce separate application and licence forms for bulk drugs (both active and inactive substances). Currently, a single licence applies to the wholesale sale of both formulations and bulk drugs. The proposed amendment is intended to establish a distinct licensing framework for bulk drugs, allowing for more targeted regulatory oversight of their wholesale sale and increased accountability within the pharmaceutical supply chain.\n\nThe Drugs Consultative Committee (DCC) and the Drugs Technical Advisory Board (DTAB) have both approved the proposal. Under the new framework, the licensing will encompass the categories of bulk drugs managed by wholesalers, including those drugs under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985. Wholesalers will be required to obtain a separate licence for the sale of bulk drugs, with the sale to be conducted under the supervision of a qualified individual. This step aims to strengthen accountability in the distribution and handling of bulk drugs.\n\nPublic comments on the proposed amendment are currently being accepted, and the Ministry encourages stakeholders and members of the public to submit their objections and suggestions.",
  "summary": "Draft amendments to the New Drugs and Clinical Trials Rules, 2019, and the Drugs Rules, 1945, would require manufacturers of antimicrobials to obtain Central Licensing Authority permission before applying for a State licence, amid concerns over antimicrobial resistance, and introduce separate forms for the wholesale sale of bulk drugs",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}